Design and Analysis of Oncology Clinical Trials
暂无分享,去创建一个
[1] B. Storer. Phase I Trials , 2005 .
[2] S. Piantadosi. Clinical Trials : A Methodologic Perspective , 2005 .
[3] P. Thall,et al. New designs for phase 2 clinical trials. , 2003, Blood.
[4] Anastasia Ivanova,et al. Improved up‐and‐down designs for phase I trials , 2003, Statistics in medicine.
[5] Gary L Rosner,et al. Randomized discontinuation design: application to cytostatic antineoplastic agents. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Parmar,et al. Designing randomised trials: both large and small trials are needed. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Katherine S Panageas,et al. An optimal two-stage phase II design utilizing complete and partial response information separately. , 2002, Controlled clinical trials.
[8] J. Karlawish,et al. The continuing unethical conduct of underpowered clinical trials. , 2002, JAMA.
[9] R. Schilsky,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.
[10] D. Spiegelhalter,et al. Monitoring of large randomised clinical trials: a new approach with Bayesian methods , 2001, The Lancet.
[11] S H Jung,et al. Graphical search for two-stage designs for phase II clinical trials. , 2001, Controlled clinical trials.
[12] J. Pignon,et al. Meta-analyses of randomised clinical trials in oncology. , 2001, The Lancet. Oncology.
[13] D. Moher,et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Annals of internal medicine.
[14] D. Moher,et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.
[15] D H Leung,et al. Isotonic designs for phase I trials. , 2001, Controlled clinical trials.
[16] R Simon,et al. Clinical trial designs for cytostatic agents: are new approaches needed? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J G Ibrahim,et al. Longitudinal design for phase I clinical trials using the continual reassessment method. , 2000, Controlled clinical trials.
[18] Y K Cheung,et al. Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.
[19] R. Simon,et al. A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. , 2000, Journal of the National Cancer Institute.
[20] R J Carroll,et al. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. , 2000, Controlled clinical trials.
[21] Geert Molenberghs,et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.
[22] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[23] T. Chen,et al. Optimal two-stage designs for phase ii clinical trials with differentiation of complete and partial responses , 2000 .
[24] B. Turnbull,et al. Group Sequential Methods with Applications to Clinical Trials , 1999 .
[25] S. Anderson,et al. Sample size determination in complex clinical trials comparing more than two groups for survival endpoints. , 1998, Statistics in medicine.
[26] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[27] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[28] T. Chen,et al. Optimal three-stage designs for phase II cancer clinical trials. , 1997, Statistics in medicine.
[29] Stephanie Green,et al. Clinical Trials in Oncology , 1997 .
[30] D. Heitjan,et al. Bayesian interim analysis of phase II cancer clinical trials. , 1997, Statistics in medicine.
[31] R Simon,et al. Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.
[32] R. Simon,et al. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M R Conaway,et al. Designs for phase II trials allowing for a trade-off between response and toxicity. , 1996, Biometrics.
[34] R Simon,et al. Assessing whether to perform a confirmatory randomized clinical trial. , 1996, Journal of the National Cancer Institute.
[35] D. Berry. When is a confirmatory randomized clinical trial needed? , 1996, Journal of the National Cancer Institute.
[36] John O'Quigley,et al. Consistency of continual reassessment method under model misspecification , 1996 .
[37] J. Bryant,et al. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.
[38] J H Shih,et al. Sample size calculation for complex clinical trials with survival endpoints. , 1995, Controlled clinical trials.
[39] S. Goodman,et al. Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.
[40] M R Conaway,et al. Bivariate sequential designs for phase II trials. , 1995, Biometrics.
[41] P. Thall,et al. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.
[42] D A Berry. Decision analysis and Bayesian methods in clinical trials. , 1995, Cancer treatment and research.
[43] Peter F. Thall,et al. Recent Advances in Clinical Trial Design and Analysis , 1995, Cancer Treatment and Research.
[44] L V Rubinstein,et al. A comparison of two phase I trial designs. , 1994, Statistics in medicine.
[45] P F Thall,et al. An optimal three-stage design for phase II clinical trials. , 1994, Statistics in medicine.
[46] S L George,et al. Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. , 1994, Statistics in medicine.
[47] D J Spiegelhalter,et al. The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee. , 1994, Statistics in medicine.
[48] P F Thall,et al. Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.
[49] D. Faries,et al. Practical modifications of the continual reassessment method for phase I cancer clinical trials. , 1994, Journal of biopharmaceutical statistics.
[50] B E Storer,et al. Small-sample confidence sets for the MTD in a phase I clinical trial. , 1993, Biometrics.
[51] P Y Liu,et al. Selection designs for pilot studies based on survival. , 1993, Biometrics.
[52] T M Therneau,et al. How many stratification factors are "too many" to use in a randomization plan? , 1993, Controlled clinical trials.
[53] J O'Quigley,et al. Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. , 1992, Biometrics.
[54] S Hellman,et al. Of mice but not men. Problems of the randomized clinical trial. , 1991, The New England journal of medicine.
[55] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[56] B E Storer,et al. Design and analysis of phase I clinical trials. , 1989, Biometrics.
[57] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[58] R. Wittes,et al. Research Methods in Clinical Oncology , 1988 .
[59] E. Lakatos,et al. Sample sizes based on the log-rank statistic in complex clinical trials. , 1988, Biometrics.
[60] H. Rockette,et al. Limitations and advantages of meta-analysis in clinical trials. , 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[61] J M Lachin,et al. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. , 1986, Biometrics.
[62] E. Marubini,et al. The use of historical controls in breast cancer. An assessment in three consecutive trials. , 1985, Controlled clinical trials.
[63] S S Ellenberg,et al. Randomized phase II clinical trials. , 1985, Cancer treatment reports.
[64] W. Dupont. Randomized vs. historical clinical trials. Are the benefits worth the cost? , 1985, American journal of epidemiology.
[65] Gail Mh. Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials. , 1985 .
[66] M. Buyse,et al. Cancer Clinical Trials: Methods and Practice. , 1985 .
[67] C. Moertel. Improving the efficiency of clinical trials: a medical perspective. , 1984, Statistics in medicine.
[68] E. Gehan,et al. The evaluation of therapies: historical control studies. , 1984, Statistics in Medicine.
[69] C. Redmond,et al. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. , 1983, Cancer treatment reports.
[70] D. Harrington. A class of rank test procedures for censored survival data , 1982 .
[71] T R Fleming,et al. One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.
[72] L. Freedman. Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.
[73] D. Byar. Why data bases should not replace randomized clinical trials. , 1980, Biometrics.
[74] R. Prentice. Linear rank tests with right censored data , 1978 .
[75] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[76] I. Todd,et al. The Design of Clinical Trials in Cancer Therapy , 1972, British Journal of Cancer.
[77] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[78] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[79] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[80] E. Gehan. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.
[81] E. Gehan,et al. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.
[82] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .